AVITA Medical Reports Q1 2026 Results: Revenue Up 4%, Net Loss Narrows, Reaffirms Full-Year Guidance

summarizeSummary

AVITA Medical reported improved Q1 2026 financial results with revenue growth and reduced net loss, while reaffirming full-year guidance, despite continued cash burn.

check_boxKey Events

• Q1 2026 Financial Performance

  Total revenue increased 4% year-over-year to $19.3 million, with operating expenses down 11% and net loss narrowing to $10.6 million.

• Cash Position and Outlook

  The company used $9.9 million in net cash, ending the quarter with $14.3 million, but anticipates a significant decrease in cash use for Q2.

• Full-Year Guidance Reaffirmed

  AVITA Medical reiterated its 2026 revenue guidance of $80 to $85 million, representing 12% to 19% growth.

• Operational Progress

  The company highlighted improved RECELL utilization, positive Cohealyx I data, and regulatory clearance for RECELL GO in Australia and New Zealand.

auto_awesomeAnalysis

AVITA Medical's first-quarter results show operational improvements with a 4% year-over-year revenue increase and an 11% reduction in operating expenses, leading to a narrower net loss. While the company experienced a $9.9 million net cash use, management expects this to significantly decrease in the second quarter and reaffirmed its full-year revenue guidance. These results provide an update on the company's financial health following a prior 'going concern' warning.